Watch ACUT. Know when insiders buy.
One email the day a filing lands. Free.
ACUT
Accustem Sciences Inc.
0.16
+0.00 +0.00%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
75
PASS · shorts 75
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$1.7MNET CASH —52W 0.15 – 1.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $98K | — | — | −$253K | −$253K | — | -0.02 | −$249K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$486K | −$486K | — | -0.03 | −$374K | — | — | May 15 |
| Q4 2025 · Dec 31derived | — | — | — | −$514K | −$514K | — | -0.04 | $22K | — | — | Apr 14 |
| Q3 2025 · Sep 30 | — | — | — | −$400K | −$400K | — | -0.02 | −$604K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$401K | −$401K | — | -0.02 | $22K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$440K | −$440K | — | -0.03 | −$290K | — | — | May 15 |
| Q4 2024 · Dec 31derived | — | — | — | −$372K | −$372K | — | -0.03 | $414 | — | — | Apr 14 |
| Q3 2024 · Sep 30 | — | — | — | −$328K | −$328K | — | -0.03 | −$218K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$278K | −$278K | — | -0.02 | −$209K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$527K | −$527K | — | -0.05 | −$237K | — | — | May 20 |
| Q4 2023 · Dec 31derived | — | — | — | −$246K | −$246K | — | -0.02 | −$295K | — | — | Apr 3 |
| Q3 2023 · Sep 30 | — | — | — | −$599K | −$599K | — | -0.05 | −$352K | — | — | Nov 18 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$1.8M | −$1.8M | — | -0.12 | −$850K | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$1.5M | −$1.5M | — | -0.13 | −$664K | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$2.1M | −$2.1M | — | -0.18 | −$1.6M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$3.7M | −$3.7M | — | -0.34 | −$1.8M | $11K | −$1.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$671K | −$671K | — | -0.07 | — | — | — | — | — |
Every number comes from Accustem Sciences Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.